FIG 9.

The PKC inhibitor Gö6983 abolishes the corepressor-coactivator switch of BCL11B on the IL-2 promoter. (A and B) Jurkat cells were treated with DMSO or activated with P/I for 30 min without or with preincubation with the PKC inhibitor Gö6983. RT-qPCR experiments were performed to analyze the expression levels of BCL11B and IL-2. (C and D) Relative occupancy of BCL11B, MTA1, RbAp48, and P300 on IL-2 promoter during Jurkat cell activation with or without treatment with the PKC inhibitor Gö6983. The level of binding was assessed by ChIP-qPCR experiments in triplicate before and after activation and inhibitor treatment as described for panels A and B. Error bars indicate standard deviations. The ChIP results for the US1 site in the IL-2 promoter are shown on the left, whereas those for the GAPDH promoter used as a nonbinding control are shown on the right. Values that are statistically significantly different are indicated by bars and asterisks as follows: *, P < 0.05; **, P < 0.01. Values that are not statistically significantly different (NS) are also indicated.